New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.60
0.15
+0.09%
Follow AZN
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $4.0B covered $1.8B of dividends and buybacks. Cash rose by $3.0B. What is a cash flow statement?
- Free cash flow
- $4.0B 85.5% of operating cash flow
- Returned to shareholders
- $1.8B 44.3% of free cash flow
- Debt, net
- $2.0B borrowed
- Change in cash
- +$3.0B over the period
| Operating cash flow | 4.7 |
|---|---|
| Capital expenditures | −0.7 |
| Free cash flow | 4.0 |
| Into investments, net | −0.2 |
| Dividends | −1.7 |
| Buybacks, net | −0.1 |
| Debt raised, net | +2.0 |
| Other | −1.0 |
| Change in cash | 3.0 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $2.3B | $3.4B | $2.9B | $4.7B |
| Capex | −$1.0B | −$539M | −$759M | −$675M |
| Free cash flow | $1.3B | $2.8B | $2.1B | $4.0B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
2,629.00 | 3,914.00 | 2,799.00 | 3,958.00 |
Depreciation & Amortization |
1,511.00 | 1,366.00 | 1,929.00 | 1,605.00 | |
Non Cash Items (Other) |
302.00 | 46.00 | 289.00 | 495.00 | |
Change in other assets and liabilities |
— | (1,000.00) | (438.00) | (292.00) | |
Other operating activities |
(899.00) | (967.00) | (1,714.00) | (1,100.00) | |
Operating Cash Flow |
2,342.00 | 3,359.00 | 2,865.00 | 4,666.00 | |
Capital expenditures |
(1,033.00) | (539.00) | (759.00) | (675.00) | |
Change in intangibles (net) |
(211.00) | (946.00) | (2,222.00) | (514.00) | |
Net Aquisitions |
(273.00) | — | — | — | |
Short Term Investments Change (Net) |
9.00 | (85.00) | 40.00 | (151.00) | |
Long-Term Investments Change (Net) |
(11.00) | (32.00) | 3.00 | 0.00 | |
Other investing activities |
73.00 | (190.00) | 26.00 | 345.00 | |
Investing cash flow |
(1,446.00) | (1,792.00) | (2,912.00) | (1,885.00) | |
Repayment/Issuance of Debt (Net) |
(3,120.00) | 4,228.00 | (2,551.00) | 2,007.00 | |
Equity Repurchase (Common, Net) |
10.00 | (602.00) | (40.00) | (101.00) | |
Dividends Paid (Total) |
(3.00) | (3,287.00) | (1.00) | (1,667.00) | |
Other financial activities |
(169.00) | (72.00) | 0.00 | 20.00 | |
Financing cash flow |
(3,282.00) | 267.00 | (2,592.00) | 259.00 | |
Exchange Rate Adjustment |
4.00 | (18.00) | 9.00 | (7.00) | |
Change in Cash |
(2,382.00) | 1,816.00 | (2,630.00) | 3,033.00 | |
Beginning Cash |
0.00 | 5,698.00 | 0.00 | 0.00 | |
Ending Cash |
(2,382.00) | 7,514.00 | (2,630.00) | 3,033.00 | |
Dividends Paid (Common) |
(3.00) | (3,287.00) | (1.00) | (1,667.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(1,201.00) | (1,000.00) | (438.00) | (292.00) | |
Investments Change (Net) |
(2.00) | (117.00) | 43.00 | (151.00) | |
Issuance/Purchase of Shares |
10.00 | (602.00) | (40.00) | (101.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026